NIAID Animal Models of Infectious Diseases 2010-2017

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, awarded a Master IDIQ on March 22, 2010, to support development and provision of animal models for infectious disease research, but ordering closed on March 21, 2017, and the vehicle is no longer active.

The vehicle established 170 task orders totaling $243.3 million in combined potential value, of which $194.2 million (80%) has been obligated. Ordering momentum peaked in 2014 and 2015, with 19 orders each year before moderating to 16 annually in 2016–2017. A successor vehicle, NIAID Preclinical Models of Infectious Diseases 2017–2024, was awarded July 13, 2017.

Awarded task orders contracted development and provision of small and large animal models for vaccine and therapeutic testing across multiple infectious agents. Representative work includes mouse models for influenza, enterovirus, and mycobacterial infection; cotton rat and ferret models for respiratory syncytial virus and influenza evaluation; non-human primate models for filovirus, tularemia, anthrax, and poliovirus research; and specialized assays and reagent production for parasites and pathogens including Zika, Ebola, and Clostridium difficile. Work spans Cost No Fee, Cost Plus Fixed Fee, and Firm Fixed Price structures, with task-order ceilings typically in the range of $300,000 to $3 million.

Five primes captured 38% of task-order count: Utah State University (21 orders, $22.2 million), University of Texas Medical Branch at Galveston (12 orders, $29.1 million), Battelle Memorial Institute (12 orders, $17.1 million), Bioqual, Inc. (11 orders, $13.1 million), and University of Texas Health Science Center at San Antonio (9 orders, $10.8 million). Activity is otherwise distributed across 34 additional contractors, including Colorado State University, University of Georgia, and numerous smaller research institutions and contract organizations. The top five primes by potential value—led by University of Texas Medical Branch, Utah State, and Colorado State—held 43% of combined potential value.

All 170 task orders were unrestricted competitive awards with no set-aside designations. Funding flowed almost entirely through NIAID's internal accounts, with roughly 85% of orders and $206.2 million potential value serving NIAID divisional programs and 15% routed through NIAID DEA OA Acquisitions.

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID's Division of Microbiology and Infectious Diseases (DMID) has awarded a Master IDIQ for providing and developing animal models in order to advance understanding of infectious diseases as well as development of therapeutics and vaccines for infectious diseases.